Dose Insider / Outsourcing pharmacies / Imprimis NJOF, LLC

Imprimis NJOF, LLCFDA registration and inspection record

FDA list of November 17, 2026 · checked against fda.gov on November 20, 2026

Imprimis NJOF, LLC in Ledgewood, New Jersey is registered with FDA as a 503B outsourcing facility, first on November 12, 2016 and most recently on November 26, 2025. FDA last inspected it on August 18, 2026 and issued a Form 483 with 6 observations.

6 observationsin the Form 483 of FDA’s inspection on August 18, 2026
Observations in the last Form 483FDA inspection reports of registered outsourcing facilitiesImprimis NJOF, LLC6Median facility5Most in one report16Observations in the lastForm 483FDA inspection reports of registered outsourcingfacilitiesImprimis NJOF, LLC6Median facility5Most in one report16

Imprimis NJOF, LLC had more observations than the median inspected facility.

On this page

These facts come from FDA’s list of registered outsourcing facilities, updated November 17, 2026, and from the inspection report FDA posted with it.1 None of the 164 FDA warning letters about GLP-1 drugs in our database names this company.

What does FDA’s record show, in brief?

FacilityImprimis NJOF, LLC
LocationLedgewood, New Jersey
Type503B outsourcing facility
Registered sinceNovember 12, 2016
Latest registrationNovember 26, 2025
Last FDA inspectionAugust 18, 2026
Inspection dates08/04/2026 to 08/18/2026
Form 483Issued, 6 observations
FDA action after the inspectionOpen
Compounds sterile drugs from bulkYes
FDA warning letters on GLP-1 drugs0

What did FDA’s investigators observe?

The Form 483 from the inspection of 08/18/2026 lists 6 observations. We sorted them by what each one is about, from the words of its opening sentence; the full wording is in FDA’s document.2

What the observation is aboutObservations
Sterility and aseptic processing2
Written procedures and quality unit1
Testing and release of batches1

FDA’s scan of the form is an image with a text layer; we do not quote it here because the text layer misreads some letters. Read the original on fda.gov.

Has this facility recalled any drugs?

FDA’s enforcement reports list 21 recalled products from this facility, from December 17, 2020 to December 18, 2025: 14 in Class II, 7 in Class III. None of them names a GLP-1 drug. Class I is the most serious: FDA uses it when the product could cause serious harm.3

StartedClassProductReason
2025-12-18IITri-Moxi+¿ (Triamcinolone 9mg/0.6mLPresence of particulate matter - Glass like particles.
2025-12-18IIDexamethasone Moxifloxacin KetorolacPresence of particulate matter - Glass like particles.
2025-12-18IIDexamethasone MoxifloxacinPresence of particulate matter - Glass like particles.
2025-10-20IIIKlarity-C Drops (Cyclosporine) 0.1%Subpotent Drug
2025-07-09IIITropicamide-Proparacaine-Phenylephrine-KetorolacSub-Potent Drug: Subpotent assay results during stability testing.
2025-07-09IIEpinephrine Lidocaine HCLSub-Potent Drug: Subpotent assay results during stability testing.
2025-02-24IIITropicamide - Proparacaine - Phenylephrine - Ketorolac Sterile OphthalSub-Potent Drug: The stability batch showed a subpotent result, which does not meet the product specifications of 90.0-1…
2024-05-14IIPrednisolone-Moxifloxacin-Bromfenac Sterile Ophthalmic SuspensionLack of Assurance of Sterility

The table shows 8 of the 21 recalls; the rest are in FDA’s enforcement reports.

Is the pharmacy behind my prescription on FDA’s list?

Type a pharmacy name or city. The search runs over all 100 facilities on FDA’s list; a 503A pharmacy that compounds for individual prescriptions is licensed by its state and is not on this list.

Pharmacy check100 facilities
Registered 503B—
With a Form 483—

Where are the registered outsourcing facilities?

8 of the 100 facilities on FDA’s list are in New Jersey. The chart counts them by state; choose a view to see which ones FDA has inspected.

Facilities by stateFDA list, November 17, 2026
Show
Facilities—
Top state—

Which other facilities are in the same state?

What does it mean that a pharmacy is a 503B outsourcing facility?

An outsourcing facility is a compounder that has chosen to register with FDA under section 503B of the Federal Food, Drug, and Cosmetic Act. It must re-register every year between October 1 and December 31 and pay an annual fee; a facility that does not is removed from FDA’s list on January 1.1 Once registered, it joins the list of facilities FDA plans to inspect on a risk-based schedule.1

A Form FDA 483 lists what investigators observed during an inspection. FDA states that a 483 is issued when investigators see significant objectionable conditions, and that it is not a final agency determination that the law was broken.1 Registration is not FDA approval of the drugs a facility makes: compounded drugs are not FDA-approved.

Sources

  1. FDA. Facilities registered as human drug compounding outsourcing facilities under section 503B, updated November 17, 2026, with its notes on registration and inspections. fda.gov
  2. FDA. Form FDA 483, inspection of Imprimis NJOF, LLC, 08/04/2026 to 08/18/2026. fda.gov
  3. FDA. Drug recall enforcement reports for Imprimis NJOF, LLC, read through openFDA on November 20, 2026. open.fda.gov

Log every dose in mg with the vial it came from, so there is a record if something goes wrong.

Open Dose Insider